Senti Bioscience Stock Price, News & Analysis

Senti Biosciences (NASDAQ:SNTI), a clinical-stage biotech company, has reported its Q2 2025 financial results and provided key updates on its SENTI-202 program for Acute Myeloid Leukemia (AML). The company has completed the dose-finding phase and confirmed the recommended Phase 2 dose (RP2D) in its ongoing Phase 1 clinical trial. SENTI-202 received FDA Orphan Drug Designation for AML treatment.

Financial highlights include cash position of $21.6M as of June 30, 2025 (down from $48.3M in December 2024), R&D expenses of $10.0M (up $0.8M YoY), and G&A expenses of $6.8M (up $2.6M YoY). The company reported a net loss of $14.7M ($0.56 per share) for Q2 2025. Additionally, Senti Bio secured a $1.0M grant from CIRM for SENTI-202's clinical development.

Senti Biosciences (Nasdaq: SNTI) has determined the recommended Phase 2 dose (RP2D) for its Phase 1 study of SENTI-202, a first-in-class Logic Gated CAR-NK cell therapy for treating relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).

The RP2D was established at 1.5 x 109 CAR+ NK cells/dose, administered on Days 0, 7, and 14 of 28-Day Cycles. Early efficacy data shows promising results with 2 of 3 patients achieving composite Complete Remission (cCR) in the preliminary RP2D cohort, and 5 of 7 evaluable patients achieving Overall Response Rate (ORR). All complete remission patients (4 of 4) were MRD-negative, with durability extending to 8+ months.

The company expects to report topline data from the expansion cohort before year-end 2025. SENTI-202 has received FDA Orphan Drug Designation.

Senti Biosciences (NASDAQ:SNTI), a clinical-stage biotechnology company, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. The company's Co-Founder and CEO, Dr. Timothy Lu, presented at the event, sharing insights about his journey, dedication to the company, and passion for their development programs.

The presentation, which focuses on Senti's proprietary Gene Circuit platform for next-generation cell and gene therapies, is now available for viewing on virtualinvestorco.com and the company's investor relations website.

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company, announced that its Chief Medical Officer, Dr. Kanya Rajangam, will deliver a presentation at the BioScience Forum on July 23, 2025 in San Carlos, CA.

The presentation, titled "Using Logic Gated CARs to Drive Cancer Treatment," will showcase Senti Bio's innovative logic-gated CAR-NK cell therapy technology, which is designed to target leukemic cells while preserving healthy bone marrow. The BioScience Forum serves the Bay Area biotechnology community by featuring discussions on cutting-edge discoveries in therapeutic areas including oncology and infectious diseases.

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company developing Gene Circuit-based cell and gene therapies, has appointed Bryan Baum to its Board of Directors. Baum, Co-Founder and Managing Partner of K5 Global, brings extensive entrepreneurial and investment experience with investments in major companies like SpaceX, OpenAI, and Uber.

As a serial entrepreneur, Baum has founded and successfully sold multiple companies, including Parrot (sold to Filevine), Blue Vision Labs (sold to Lyft), and Represent.com (sold to CustomInk). His expertise in scaling successful companies and strategic insights will support Senti Bio's development of Logic Gated cell therapies for cancer treatment.

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company, participated in Nasdaq's Amplify Spotlight Series. CEO and Co-Founder Timothy Lu presented a corporate overview highlighting the company's proprietary Gene Circuit platform for developing next-generation cell and gene therapies.

The company's lead program, SENTI-202, is a first-in-class off-the-shelf CAR NK cell therapy targeting CD33 and/or FLT3-expressing hematologic malignancies, including AML and myelodysplastic syndrome (MDS). The therapy is currently in Phase 1 clinical trials and has shown positive preliminary data. Notably, SENTI-202 has received Orphan Drug Designation from the FDA for treating relapsed/refractory hematologic malignancies including AML.

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will present at the 2025 SEED Conference in Houston, TX. The company's Co-Founder and CEO, Timothy Lu, MD, PhD, will deliver a presentation titled "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells" on June 24, 2025 at 1:20 PM CT.

The SEED Conference, established in 2014, is a premier technical event for synthetic biology professionals that has attracted over 5,000 attendees since its inception. The conference serves as a platform for sharing research, networking, and discussing advances in synthetic biology.

Senti Biosciences (NASDAQ: SNTI) has received FDA Orphan Drug Designation for SENTI-202, their first-in-class off-the-shelf Logic Gated CAR NK cell therapy targeting acute myeloid leukemia (AML). SENTI-202 is designed to selectively target CD33 and/or FLT3-expressing hematologic malignancies while protecting healthy bone marrow cells. The therapy is currently in Phase 1 clinical trials. AML affects approximately 20,800 newly diagnosed patients annually in the U.S., with a 60% relapse or death rate within 12 months and a median survival rate of 5.3 months for relapsed/refractory cases. The Orphan Drug Designation provides several benefits including tax credits, FDA fee exemptions, and potential seven-year market exclusivity upon approval.

Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotech company focused on Gene Circuit platform cell and gene therapies, has granted stock options to eight new employees. The Board approved options to purchase 102,500 shares at an exercise price of $3.03 per share on June 3, 2025. These inducement equity awards were granted under the company's Amended and Restated 2022 Inducement Equity Plan, which was initially adopted on August 5, 2022. The grants were made in accordance with NASDAQ Listing Rule 5635(c)(4) as material inducement for the new employees joining the company.